Join Dogwood Therapeutics for a virtual key opinion leader (KOL) event featuring Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), and J. Mark Joyce, M.D. (CNS Healthcare), who will join company management to discuss the unmet need and current treatment landscape for chemotherapeutic induced neuropathic pain (CINP). The Company is on track to report top-line Phase 2b results this Fall 2026 with 230 patients currently enrolled.

The event will review the novel role of the Nav 1.7 sodium ion channel in pain signaling, which is key to the initiation and conduction of the electrical signals that the brain interprets as pain. Management will discuss Halneuron^®’s selective and differentiated Nav 1.7 mechanism of action as compared to current and future Nav inhibitors. The speakers will also review prior Halneuron pre-clinical and clinical research and the design and projected treatment outcomes of the ongoing Phase 2b CINP study design. Halneuron has been tested on more than 800 patients to date, including patients suffering from cancer related pain and CINP. Guest experts will discuss ion channel therapies as a newer approach to treating chronic pain, as well as the existing unmet medical need in treating CINP. The company will provide an overview of blinded interim results from the ongoing Phase 2b clinical trial in patients with a mean duration of five years of neuropathy due to their prior chemotherapy treatment, and discuss the advancement of the first ever synthetic formulation of Tetrodotoxin to support Halneuron^®’s’ Phase 3 development.

A live question and answer session will follow the formal presentations.